Fibrocell Science,'s Revenue in the fiscal year 2018 $ 1.66 millions
Fibrocell Science,'s Revenue in the fiscal year 2017 $ 0.00 millions
Fibrocell Science,'s Revenue in the fiscal year 2016 $ 0.36 millions
Fibrocell Science,'s Revenue in the fiscal year 2015 $ 0.49 millions
Fibrocell Science,'s Revenue in the fiscal year 2014 $ 0.18 millions
FCSC Revenue third quarter 2019 Y/Y Growth Comment
Fibrocell Science, Inc. achieved in the third quarter 2019, above Company average Revenue surge of 1032.22% year on year, to $ 1.02 millions.
Looking into third quarter 2019 results within Major Pharmaceutical Preparations industry 12 other companies have achieved higher Revenue growth. While Fibrocell Science, Inc.' s Revenue doubling of 1032.22% ranks overall at the positon no. 68 in the third quarter 2019.
Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019
Fibrocell Science,'s Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
39521.82 %
1821.62 %
-100 %
(Jun 30 2019)
FCSC's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2019 Fibrocell Science, Inc. disclosed fall in Revenue from the second quarter by -95.32% to $ 1.02 millions, from $ 21.79 millions achived in the previous reporting period.
But that's not important problem, as Fibrocell Science,'s Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 277 other companies have achieved higher Revenue quarter on quarter growth. While Fibrocell Science,'s Revenue growth quarter on quarter, overall rank is 4443.
In the III. Quarter 2019 Fibrocell Science, Inc. disclosed fall in Revenue from the second quarter by -95.32% to $ 1.02 millions, from $ 21.79 millions achived in the previous reporting period.
But that's not important problem, as Fibrocell Science,'s Revenue generally seem to plunge in this quarter.
Within Major Pharmaceutical Preparations industry 277 other companies have achieved higher Revenue quarter on quarter growth. While Fibrocell Science,'s Revenue growth quarter on quarter, overall rank is 4443.
Fibrocell Science,'s 12 Months Revenue Growth Year on Year
Revenue TTM Growth
12 Months Ending (Sep 30 2019)
12 Months Ending (Jun 30 2019)
12 Months Ending (Mar 31 2019)
12 Months Ending (Dec 31 2018)
12 Months Ending (Sep 30 2018)
Cumulative Revenue 12 Months Ending
$ 24.53
$ 23.60
$ 2.05
$ 1.93
$ 0.00
Y / Y Revenue Growth (TTM)
-
-
-
-
-
Year on Year Revenue Growth Overall
Ranking
#
#
#
#
#
Seqeuential Revenue Change (TTM)
3.95 %
1053.27 %
6.12 %
-
-
Seq. Revenue Growth (TTM) Overall
Ranking
# 1654
# 991
# 536
# 0
# 0
Cumulative Revenue growth Comment
Fibrocell Science, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 1032.22% year on year, to $ 25 millions if the fiscal year would have ended in Sep 30 2019. Fibrocell Science,'s trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2019. And, Fibrocell Science, realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Jun 30 2019 rise was beneth at 3.95 % from $23.6 millions achieved in the period from Jun 30 2019 to Sep 30 2018. We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at42.75%.
Fibrocell Science, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
Fibrocell Science, saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 1032.22% year on year, to $ 25 millions if the fiscal year would have ended in Sep 30 2019. Fibrocell Science,'s trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Jun 30 2019. And, Fibrocell Science, realized the fastest Revenue growth, in Major Pharmaceutical Preparations industry. But from twelve months ended Jun 30 2019 rise was beneth at 3.95 % from $23.6 millions achieved in the period from Jun 30 2019 to Sep 30 2018. We witness drop-off happening, more obvious observing the When you usual Q/Q TTM historic rise that is stronger at42.75%. The momentum is even more impressive from twelve months ended Jun 30 2019 exhibited at 3.95 % increase from $23.6 millions in the period from Jun 30 2019 to Sep 30 2018.
Fibrocell Science, Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .
About Fibrocell Science, Revenue Growth Rates (FCSC), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
1,713.70%